Expression of ILT 3 in Clonal Lymphoproliferative Disorders

Document Type : Original Article


1 Department of Clinical Pathology,Faculty of Medicine, Sohag University.

2 Department of Clinical and Pathology,sohag faculty of medicine,sohag university

3 Department of Clinical Pathology and Chemistry, Sohag Faculty of Medicine, Sohag University

4 Department of Clinical and Chemical Pathology, Faculty of Medicine, Sohag University


B-cell chronic lymphocytic leukemia (B-CLL), also known as chronic lymphoid leukemia (CLL), is the most common type of leukemia (a type of cancer of the white blood cells) in adults, CLL affects B cell lymphocytes,Immunoglobulin-like transcript-3 (ILT-3), a member of the immunoglobulin superfamily, is a transmembrane inhibitory receptor expressed on antigen-presenting cells (APCs) such as monocytes and dendritic cells (DCs) as well as on endothelial  cells The aims of this study was to evaluate the expression of  ILT-3 in acute and chronic leukamias and its relation to other diagnostic markers and if it has a role in leukamiogenesis A total of 5 papers were obtained using the mentioned keywords in the research of all internet-based databases
Patients and Methods: Case control study, included 30 patients 15 patients with CLLand 15patients no detectable disease recruited from Sohag university hospital and the mean age of each of them was 32.8 years.   There are different method of detection of IL3 in different studies such as PCR, ELISA and (FCM).
Results: The frequency of ILT3 positive CLL B cells was higher in patients with lymphoid tissue involvement, suggesting that ILT3 may have prognostic value in CLL

  1. Byrd and John (2014):  "Chronic Lymphocytic Leukemia".Leukemia & Lymphoma Society. Retrieved 24 March 2014 .
  2. Delgado J, Matutes E, Morrila AM, Morilla RM, Owusu-Ankomah KA, Rafig-Mohammed F, et al. (2003):  Diagnostic significance of CD20 and FMC7 expression in B-
  3. cell disorders. Am J ClinPathol. 2003;120: 754-9.
  4. Dal-Bo M, Bertoni F, Forconi F, Zucchetto A, Bomben R, Marasca R, et al. (2009):  Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia:  prognostic markers with pathogenetic relevance. J Transl Med. 2009; 7: 76-89.
  5. Ghosh S, Shinde SC, Kumaran GS, Sapre RS, Dhond SR, Badrinath Y, et al. Haematologic and immunophenotypicprofi le of acute myeloid leukemia:  An experience of Tata memorial hospital. Indian J Cancer 2003;40: 71-6
  6. Lichtman M, Kaushansky K, Kipps T, Prchal JT and Levi MM (2011):  The clonal lymphoid and plasma cell diseases:  The chronic lymphocytic leukemias. In:  Williams Manual of Hematology [ (eds.)] 8th edition, Chapter 56, Page 404-427, McGraw-Hill Companies, USA.
  7. Lin TS, Awan FT, and Byrd JC. (2008):  Chronic lymphocytic leukemia. In:  Hoffman R, Benz. Jr EJ, Shattil SJ, Furie B, Silberstein LE, McGlave P, et al., editors. Hematology:  Basic Principles and Practice. 5th ed. Churchill Livingstone/Elsevier Philadelphia, USA; 2008. ch.83.
  8. Morel E, and Bello´n T. (2011):  HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/ CD85j. J. Immunol. 2011; 181:  2368-2381. J. Immunol. 181, 2368–2381.
  9. Nakase K, Bradstock K, Sartor M, Gottlieb D, Byth K, Kita K, et al. (2000):  Geographic heterogeneity of cel-lular characteristics of acute myeloid leukemia:  a comparative study of Australia and Japan adult cases. Leukemia 2000; 14: 163-8.
  10. Weinberg OK, Seetharam M, Ren L, Seo K, Ma L, Merker JD, et al. (2009):  Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood 2009; 113 (9):  1906-8.